Onego Bio, a food ingredient company producing non-animal egg protein, and Sigma Foods ("SIGMA"), a leading multinational food company, have entered into a collaboration agreement to evaluate the functionality and commercial potential of Bioalbumen®, a non-animal egg protein made with using precision fermentation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305756400/en/ The partnership focuses on advancing ingredient innovati...
FPT AI Factory announced the buildout of its next-generation AI infrastructure, accelerated by NVIDIA HGX B300 systems. This marks a significant milestone in empowering AI developers and enterprises to advance AI innovation across the region with reasoning and agentic capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326685242/en/NVIDIA HGX B300 AI is shifting into a new phase where its true value will be defined by ho...
A documentary portrays the daily lives of AFP reporters in Gaza
Hélène Lam Trong's documentary, Inside Gaza, which follows the daily lives of journalists at Agence France-Presse’s Gaza bureau in the months following the attack of October 7, 2023, will be featured this autumn at several festivals and on television in Belgium, Switzerland, France, Germany, and Italy.
Partners
InVID
InVID
Awards
Awards
Awards
NHOA Energy, global provider of utility-scale energy storage systems, has been awarded two new Battery Energy Storage System (BESS) projects in Italy by a leading independent platform in the renewables and energy transition sector, with a total MACSE-contracted capacity of about 600 MWh and a total power of 90 MW. The two projects, located in Campania and Sardinia, represent NHOA Energy’s first systems awarded under MACSE (Meccanismo di Approvvigionamento di Capacità di Stoccaggio Elettrico),...
Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted Priority Review for rusfertide. Rusfertide is an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (PV). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. In a...